NEW YORK ( TheStreet) -- Novo Nordisk A/S (NYSE: NVO) hit a new 52-week high Friday as it traded at $125.02 compared with its previous 52-Week high of $122.95. Novo Nordisk A/S is changing hands at $124.77 with 289,355 shares traded as of 11:16 a.m. ET. Average volume has been 259,000 shares over the past 30 days. Novo Nordisk A/S has a market cap of $73.2 billion and is part of the health care sector and drugs industry. Shares are up 8.4% year to date as of the close of trading on Thursday. Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 27.6 and below the S&P 500 P/E ratio of 23.4. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Novo Nordisk A/S Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.